Powders, Granules Or Particles Of Specified Mesh Or Particle Size Patents (Class 514/951)

Cross-Reference Art Collections

Wettable (Class 514/952)
  • Patent number: 9012363
    Abstract: A granular agrochemical composition is disclosed including a granular core material having a water soluble portion with a first coating layer applied on the surface of the core material and a second coating layer applied on the surface of the first coating layer. The first coating layer includes a wax composition having a biologically active ingredient incorporated therein and the second coating layer includes a polymeric composition. The granular agrochemical composition exhibits a controlled rate of release of the biologically active ingredient therefrom over a period greater than about 30 days from the date of initial exposure of the granular composition to moisture whereby essentially all of the biologically active ingredient incorporated in the wax material of the first coating layer is released from the granular composition before the water soluble portion of the granular core material is released from the granular composition.
    Type: Grant
    Filed: July 26, 2013
    Date of Patent: April 21, 2015
    Assignee: Everris International B.V.
    Inventors: Lonneke Jacoba van Boxtel-Verhoeven, Johannes Gijsbertus Antonius Terlingen, Petra Leonarda Hendrica Lunde-Vannuys
  • Patent number: 8920781
    Abstract: A powder for use in a dry powder inhaler includes active particles and carrier particles for carrying the active particles. The powder further includes additive material on the surfaces of the carrier particles to promote the release of the active particles from the carrier particles on actuation of the inhaler. The powder is such that the active particles are not liable to be released from the carrier particles before actuation of the inhaler. The inclusion of additive material in the powder has been found to give an increased respirable fraction of the active material.
    Type: Grant
    Filed: March 26, 2010
    Date of Patent: December 30, 2014
    Assignee: Vectura Limited
    Inventor: John Nicholas Staniforth
  • Patent number: 8841286
    Abstract: A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a concentrated formulation of aztreonam lysinate delivered as an aerosol or dry powder formulation.
    Type: Grant
    Filed: September 26, 2011
    Date of Patent: September 23, 2014
    Assignee: Gilead Sciences, Inc.
    Inventor: Alan Bruce Montgomery
  • Patent number: 8834909
    Abstract: The invention is directed at a ready-to-use granule bait composition, its preparation and use for the control of house flies inside houses and animal stalls, fodder stores and sanitary installations.
    Type: Grant
    Filed: July 28, 2004
    Date of Patent: September 16, 2014
    Assignee: Novartis AG
    Inventors: Ferenc Jozsef Rakoczi, Jean-Louis Hug
  • Patent number: 8828359
    Abstract: Embodiments of the invention relate to particles of active substances, methods for preparing the particles, formulations containing the particles, and metered dose inhalers containing such particles or formulations. In one embodiment, a composition of an aerosol formulation is provided and contains a particulate active substance of non-micronized, solid particles having a mass median aerodynamic diameter of less than 10 ?m suspended in a hydrofluorocarbon fluid vehicle at a concentration within a range from about 0.2% w/v to about 5% w/v. The aerosol formulation exhibits a flocculation volume of about 85% or greater about 1 minute after mixing the particulate active substance and the hydrofluorocarbon fluid vehicle. The particulate active substance contains an alkaloid ergotamine, pharmaceutically acceptable salts thereof, analogs thereof, or derivatives thereof.
    Type: Grant
    Filed: June 3, 2013
    Date of Patent: September 9, 2014
    Assignee: Nektar Therapeutics
    Inventors: Andreas Kordikowski, Stephen Ernest Walker, Peter York
  • Patent number: 8821938
    Abstract: Drugs, especially low aqueous solubility drugs, are provided in a porous matrix form, preferably microparticles, which enhances dissolution of the drug in aqueous media. The drug matrices preferably are made using a process that includes (i) dissolving a drug, preferably a drug having low aqueous solubility, in a volatile solvent to form a drug solution, (ii) combining at least one pore forming agent with the drug solution to form an emulsion, suspension, or second solution and hydrophilic or hydrophobic excipients that stabilize the drug and inhibit crystallization, and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix of drug. Hydrophobic or hydrophilic excipients may be selected to stabilize the drug in crystalline form by inhibiting crystal growth or to stabilize the drug in amorphous form by preventing crystallization.
    Type: Grant
    Filed: February 8, 2011
    Date of Patent: September 2, 2014
    Assignee: Acusphere, Inc.
    Inventors: Julie Straub, David Altreuter, Howard Bernstein, Donald E. Chickering, III, Sarwat Khattak, Greg Randall
  • Patent number: 8791160
    Abstract: Disclosed are modified release oral tranexamic acid formulations and methods of treatment therewith.
    Type: Grant
    Filed: September 14, 2012
    Date of Patent: July 29, 2014
    Assignee: Ferring B.V.
    Inventors: Keith A. Moore, Ralph A. Heasley, Jeffrey S. Greiwe, John W. Facemire, Jason D. Modest
  • Patent number: 8747908
    Abstract: The present invention provides wood preservative compositions comprising micronized particles. In one embodiment, the composition comprises dispersions of micronized metal or metal compounds. In another embodiment, the wood preservative composition comprises an inorganic component comprising a metal or metal compound and organic biocide. When the composition comprises an inorganic component and an organic biocide, the inorganic component or the organic biocide or both are present as micronized particles. When compositions of the present invention are used for preservation of wood, the micronized particles can be observed as uniformly distributed within the wood and there is minimal leaching of the metal and biocide from the wood.
    Type: Grant
    Filed: October 21, 2004
    Date of Patent: June 10, 2014
    Assignee: Osmose, Inc.
    Inventors: Robert M. Leach, Jun Zhang
  • Patent number: 8679539
    Abstract: A process for preparing the drug-loaded cyanoacrylate nanoparticles is described. The cyanoacrylate nanoparticles which effectively deliver biological and therapeutic agents are synthesized by miniemulsion polymerization with surfactant, pluronic F127 or F68. Before initiation of polymerization, active agents with particularly highly hydrophobicity are dissolved in cyanoacrylate monomer. Compared with the drug-loaded polyalkylcyanoacrylate nanoparticles produced by emulsion polymerization, those produced by miniemulsion polymerization possess higher loading and encapsulation efficiencies. While the content of dissolved agents increases, furthermore, the loading and encapsulation efficiencies increase concurrently.
    Type: Grant
    Filed: January 31, 2007
    Date of Patent: March 25, 2014
    Assignee: Tong Shen Enterprise Co., Ltd.
    Inventors: Yu-Der Lee, Chi-Yu Huang, Chih-Ming Chen
  • Patent number: 8658187
    Abstract: Provided herein are beads comprising at least one structuring agent and least one powder, and a novel process for making same. In one aspect, the process includes solubilzing at least one structuring agent with a solvent in the presence of at least one powder under turbulent high shear mixing to form small, nonspherical nucleated seeds of about 3 mm or less in diameter, and thereafter allowing the nucleated seeds to accrete under laminar low shear mixing to obtain substantially spherical beads of a desired size.
    Type: Grant
    Filed: December 21, 2010
    Date of Patent: February 25, 2014
    Assignee: Avon Products Inc.
    Inventors: Raheel Khan, Donald Slade, Marsha C. Dawkins
  • Patent number: 8613953
    Abstract: The invention provides a novel method for obtaining solid micro- or nanoparticles with a homogeneous structure. A method is provided for obtaining solid micro- or nanoparticles with a homogeneous structure having a particle size of less than 10 ?m where the processed solid compound has the natural, crystalline, amorphous, polymorphic and other features associated with the starting compound. In accordance with the invention a method which also makes it possible to obtain solid micro- or nanoparticles with a substantially spheroidal morphology is provided.
    Type: Grant
    Filed: November 6, 2009
    Date of Patent: December 24, 2013
    Assignees: Consejo Superior de Investigaciones Científicas, Centro de Investigación Biomédica en Red en Bioingeniería, Biomateriales Y Nanomedicina
    Inventors: Nora Ventosa Rull, Jaume Veciana Miró, Mary Cano Sarabia, Santiago Sala Vergés
  • Patent number: 8580307
    Abstract: Absorbable microspheres comprising a copolymer formed from greater than 80 to about 99 mole percent D,L-lactide, L(?)-lactide, D(+)-lactide, or meso-lactide and combinations thereof, and about 1 to less than 20 mole percent of a different second monomer selected from the group consisting of p-dioxanone and trimethylene carbonate and combinations thereof, said microspheres having a particle size ranging from about 5 to 2000 microns. Also described herein are formulations comprising such absorbable microspheres.
    Type: Grant
    Filed: June 22, 2006
    Date of Patent: November 12, 2013
    Assignee: Ethicon, Inc.
    Inventors: Dennis D. Jamiolkowski, Modesto Erneta, Robert DiLuccio
  • Patent number: 8524829
    Abstract: The invention involves methods and products related to the micronization of hydrophobic drugs. A method of micronizing hydrophobic drugs using a set of solutions including an aqueous solution is provided. The invention also relates to products of micronized hydrophobic drugs and related methods of use.
    Type: Grant
    Filed: June 17, 2008
    Date of Patent: September 3, 2013
    Assignee: Brown University Research Foundation
    Inventors: Edith Mathiowitz, Christopher Thanos, Zhi Liu
  • Patent number: 8497229
    Abstract: A granular agrochemical composition is disclosed including a granular core material having a water soluble portion with a first coating layer applied on the surface of the core material and a second coating layer applied on the surface of the first coating layer. The first coating layer includes a wax composition having a biologically active ingredient incorporated therein and the second coating layer includes a polymeric composition. The granular agrochemical composition exhibits a controlled rate of release of the biologically active ingredient therefrom over a period greater than about 30 days from the date of initial exposure of the granular composition to moisture whereby essentially all of the biologically active ingredient incorporated in the wax material of the first coating layer is released from the granular composition before the water soluble portion of the granular core material is released from the granular composition.
    Type: Grant
    Filed: January 18, 2011
    Date of Patent: July 30, 2013
    Assignee: Everris International B.V.
    Inventors: Lonneke Jacoba van Boxtel-Verhoeven, Johannes Gijsbertus Antonius Terlingen, Petra Leonarda Hendrica Lunde-Vannuys
  • Patent number: 8481070
    Abstract: There is provided a powder formulation for nasal delivery including a protein having a molecular weight of 10 kDa or greater and chitosan or a derivative thereof or a salt of chitosan or a salt of a derivative of chitosan. Preferably the protein is human growth hormone.
    Type: Grant
    Filed: September 30, 2009
    Date of Patent: July 9, 2013
    Assignee: Archimedes Development Limited
    Inventors: Ann Margaret Dyer, Peter James Watts, Yu-Hui Cheng, Alan Smith
  • Patent number: 8470301
    Abstract: Embodiments of the invention relate to particles of active substances, methods for preparing the particles, formulations containing the particles, and metered dose inhalers containing such particles or formulations. In one embodiment, a composition of an aerosol formulation is provided and contains a particulate active substance of non-micronized, solid particles having a mass median aerodynamic diameter of less than 10 ?m suspended in a hydrofluorocarbon fluid vehicle at a concentration within a range from about 0.2% w/v to about 5% w/v. The aerosol formulation exhibits a flocculation volume of about 85% or greater about 1 minute after mixing the particulate active substance and the hydrofluorocarbon fluid vehicle. The particulate active substance contains an alkaloid ergotamine, pharmaceutically acceptable salts thereof, analogues thereof, or derivatives thereof.
    Type: Grant
    Filed: November 11, 2011
    Date of Patent: June 25, 2013
    Assignee: Nektar Therapeutics
    Inventors: Andreas Kordikowski, Stephen Ernest Walker, Peter York
  • Patent number: 8465776
    Abstract: The present invention relates to granules comprising oxycodone, as well as to orally disintegrating tablets including same and optionally acetaminophen.
    Type: Grant
    Filed: July 31, 2007
    Date of Patent: June 18, 2013
    Assignee: Ethypharm
    Inventor: Didier Hoarau
  • Patent number: 8455487
    Abstract: The invention relates to a method of controlling insects in the family Nitidulidae using the compound 4,5-di -hydro-6-methyl-4-(3-pyridylmethyleneamino)-1,2,4-triazin-3(2H)-one and also encompasses the use of compositions comprising 4,5-dihydro-6-methyl-4-(3-pyridylmethyleneamino)-1,2,4-triazin-3(2H)-one for controlling Nitidulidae, in particular pollen beetles as well as the preparation of said compound and/or compositions for use in controlling Nitidulidae. In particular, the invention relates to the use of 4,5-dihydro-6-methyl-4-(3-pyridylmethyleneamino)-1,2,4-triazin-3(2H)-one and/or compositions comprising this compound in controlling such insects in crops of useful plants, in particular flowering crops and/or flowering ornamental plants.
    Type: Grant
    Filed: May 20, 2008
    Date of Patent: June 4, 2013
    Assignee: Syngenta Participations AG
    Inventors: Pascal Chollet, Domingos Pedroni, Stephen Wilson Skillman
  • Patent number: 8367116
    Abstract: The invention provides compositions and methods for treating a subject who has suffered from a central nervous system disorder. More particularly, the invention provides sustained polymeric drug delivery systems having a polymer particle, a therapeutic agent, and a buoyancy agent for direct delivery of therapeutic agents into the central nervous system.
    Type: Grant
    Filed: March 18, 2011
    Date of Patent: February 5, 2013
    Assignee: Seacoast Neuroscience, Inc.
    Inventors: Daniel Pratt, Samuel S. Macausland, Keith Baker
  • Patent number: 8343483
    Abstract: New strains of Lactobacillus that have been selected for their capability of improved reduction the number of Streptococcus mutans in the mouth of mammals through inhibiting activity in combination with better binding to the oral mucins and dental plaque, thereby preventing, reducing or treating dental caries, and products derived from said strains, including agents for treatment or prophylaxis of caries for administration to humans.
    Type: Grant
    Filed: October 15, 2008
    Date of Patent: January 1, 2013
    Assignee: Biogaia AB
    Inventors: Bo Mollstam, Eamonn Connolly
  • Patent number: 8288169
    Abstract: Materials and methods for surface mediated self-assembly of nanoparticles for the isolation of biomolecules is provided.
    Type: Grant
    Filed: March 24, 2008
    Date of Patent: October 16, 2012
    Assignee: Argylla Technologies
    Inventors: Joseph G. Utermohlen, Michael E. Hogan, Paul E. Diggins
  • Patent number: 8128909
    Abstract: Disclosed is a process for the preparation of sterile aqueous suspensions based on active ingredients in the form of micronised crystalline particles designed for administration by inhalation. In particular, a process for the preparation of sterile aqueous suspensions based on pharmaceutical active ingredients in the form of crystalline hydrates is disclosed.
    Type: Grant
    Filed: December 17, 2003
    Date of Patent: March 6, 2012
    Assignee: Chiesi Farmaceutici S.p.A.
    Inventors: Andrea Capocchi, Fausto Pivetti
  • Patent number: 8128912
    Abstract: Dermatological methods of cosmetic, therapeutic, prophylactic, and/or diagnostic treatment by topically applying compositions comprising a multiplicity of particles, at least one of the particles comprising porous and/or polycrystalline silicon. Included are methods and compositions for sun protection applications. The use of porous silicon, polycrystalline silicon, and porous silicon oxide mirrors is disclosed.
    Type: Grant
    Filed: June 2, 2005
    Date of Patent: March 6, 2012
    Assignee: pSIMEDICA Limited
    Inventors: Leigh T Canham, Roger Aston
  • Patent number: 8101209
    Abstract: The invention relates to a microparticulate system for the delayed and controlled release of active principles (AP) whose absorption window in vivo is essentially limited to the upper parts of the gastrointestinal tract, this system being intended for oral administration. The object of the invention is to provide a system ensuring that the AP is released with certainty by means of a dual mechanism of “time-dependent” and “pH-dependent” release. To achieve this object, the invention proposes a multimicrocapsular oral galenical form which is designed so as to guarantee therapeutic efficacy, and in which the release of the AP is governed by a dual release triggering mechanism that is “time-triggering” and “pH-triggering”. This system comprises of microcapsules (200 to 600 ?m) comprising a core of AP coated with a film (maximum 40% by weight) comprising a hydrophilic polymer A (Eudragit® L) and a hydrophobic compound B (vegetable wax, melting point=40-90° C.), B/A being between 0.2 and 1.5.
    Type: Grant
    Filed: April 19, 2004
    Date of Patent: January 24, 2012
    Assignee: Flamel Technologies
    Inventors: Valérie Legrand, Catherine Castan, Rémi Meyrueix, Gérard Soula
  • Patent number: 8080236
    Abstract: Embodiments of the invention relate to particles of active substances, methods for preparing the particles, formulations containing the particles, and metered dose inhalers containing the particles or formulations. In one embodiment, an inhaler contains an aerosol formulation containing a particulate active substance of non-micronized, solid particles having a mass median aerodynamic diameter of less than 10 ?m. The particles may be suspended in a nonsolvent hydrofluorocarbon fluid vehicle (e.g., HFA 134a or 227ea) at a concentration within a range from about 0.2% w/v to about 5% w/v. The formulation exhibits a flocculation volume of about 85% or greater about 1 minute after mixing the particulate active substance and the vehicle. The particulate active substance may contain salmeterol xinafoate, budesonide, salbutamol sulfate, dihydroergotamine mesylate, risperidone-(9-hydroxy)-palmitate, bromocriptine mesylate, or derivatives thereof. In some examples, the active substance is dihydroergotamine mesylate.
    Type: Grant
    Filed: June 12, 2009
    Date of Patent: December 20, 2011
    Assignee: Nektar Therapeutics UK, Ltd
    Inventors: Andreas Kordikowski, Stephen Ernest Walker, Peter York
  • Patent number: 8012508
    Abstract: The present invention relates to method of targeting therapeutic agents for treating lung diseases.
    Type: Grant
    Filed: January 15, 2008
    Date of Patent: September 6, 2011
    Assignee: Abbott Cardiovascular Systems Inc.
    Inventor: Florian N. Ludwig
  • Patent number: 7994157
    Abstract: Disclosed are a method for dispersing plant sterol for beverage and a plant sterol-dispersed beverage, of which particle size is nanometer-scale in dispersed beverage. The dispersion of plant sterols starts with the admixing of plant sterol to at least one emulsifier selected from the group consisting of sucrose fatty acid ester, sorbitan fatty acid ester and polyglycerine fatty acid ester, followed by melting the admixture by heating at 60 to 200° C. Afterwards, the molten substance is mixed with an aqueous beverage alone or an emulsifier-containing aqueous beverage in state of its own molten type or power type. This resulting mixture is stirred at a high speed to give a dispersion of plant sterols in an aqueous beverage. The beverage is superior in bioavailability, having good mouth feel, transparent aspect and no influence on the characteristic taste, flavor and color of the beverages.
    Type: Grant
    Filed: September 28, 2001
    Date of Patent: August 9, 2011
    Assignee: KIP Biotech LLC
    Inventors: Won-Tae Yoon, Kab-Sig Kim, Bo-Chun Kim, Jung-Hee Han, Hyung-Pyo Hong
  • Patent number: 7972623
    Abstract: The invention relates to a method for producing effervescent granules, in which the reaction partners edible, organic acid components and alkaline effervescent components separating carbon dioxide are reacted with each other in a vacuum under the effect of gas in a container that can be evacuated. The container is evacuated to a first vacuum value within a vacuum range of 200-900 mbar, whereupon the pressure inside the container is increased to a second vacuum value as a result of the gases produced during the reaction. The steps are cyclically repeated while the reaction continues. A maximum number of cycles, a maximum reaction time, and optionally, a maximum load for the stirring apparatus are defined before the reaction begins, and the reaction is terminated after reaching the first of the maximums.
    Type: Grant
    Filed: August 7, 2004
    Date of Patent: July 5, 2011
    Assignee: Dr. Gergely & Co.
    Inventors: Irmgard Gergely, Thomas Gergely, Stefan Gergely
  • Patent number: 7923032
    Abstract: The invention provides compositions and methods for treating a subject who has suffered from a central nervous system disorder. More particularly, the invention provides sustained polymeric drug delivery systems having a polymer particle, a therapeutic agent, and a buoyancy agent for direct delivery of therapeutic agents into the central nervous system.
    Type: Grant
    Filed: November 26, 2003
    Date of Patent: April 12, 2011
    Assignee: Seacoast Neuroscience, Inc.
    Inventors: Daniel Pratt, Samuel S. MacAusland, Keith Baker
  • Patent number: 7842377
    Abstract: A composition includes a plurality of particles. At least some of the plurality of particles include cross-linked polyvinyl alcohol and have a diameter of about 500 microns or less. The particles have a first average pore size in an interior region, and a second average pore size at a surface region. The first average pore size being greater than the second average pore size. The composition also includes a carrier fluid. The plurality of particles being in the carrier fluid.
    Type: Grant
    Filed: September 23, 2008
    Date of Patent: November 30, 2010
    Assignee: Boston Scientific Scimed, Inc.
    Inventors: Janel Lanphere, Ernest J. St. Pierre, Greg Kapoglis, Thomas V. Casey, II
  • Patent number: 7731790
    Abstract: The invention concerns a conditioned composition comprising at least a liquid absorbed on a support containing a precipitated silica, said silica being in the form of substantially spherical beads and having: a mean pellet size greater than 150 ?m; a filling density in compact state(DRT) greater than 0.29; an oversize rate for a grid with mesh aperture size of 75 ?m of at least 92% by weight. The invention also concerns the use of such a silica as a support for liquid.
    Type: Grant
    Filed: February 18, 2005
    Date of Patent: June 8, 2010
    Assignee: Rhodia Chimie
    Inventor: Jean-François Viot
  • Patent number: 7718163
    Abstract: A powder for use in a dry powder inhaler includes active particles and carrier particles for carrying the active particles. The powder further includes additive material (4) on the surfaces of the carrier particles to promote the release of the active particles from the carrier particles on actuation of the inhaler. The powder is such that the active particles are not liable to be release from the carrier particles before actuation of the inhaler. The inclusion of additive material (4) in the powder has been found to give an increased respirable fraction of the active material.
    Type: Grant
    Filed: August 11, 2005
    Date of Patent: May 18, 2010
    Assignee: Vectura Limited (01696917)
    Inventor: John Nicholas Staniforth
  • Patent number: 7695737
    Abstract: Spherical composite particles are formed of inorganic fine particles and resin fine particles joined together, and an average particle diameter is in the range from 1.1 to 100 ?m, in which the average particle diameter of the inorganic fine particles is in the range from 5 to 600 nm and the average particle diameter of the resin fine particles is in the range from 10 to 500 nm. The inorganic fine particle and the resin fine particle have almost the same size, and the hardness, softness, and adaptability when spreading on a skin can finely be adjusted as desired in a wide range according to the contact feeling required for the cosmetics in which the particles are blended.
    Type: Grant
    Filed: March 6, 2003
    Date of Patent: April 13, 2010
    Assignee: JGC Catalysts & Chemocals Ltd.
    Inventors: Takumi Miyazaki, Hirokazu Tanaka
  • Patent number: 7670625
    Abstract: The invention relates to a stable pharmaceutical composition useful in the treatment of respiratory disorders such as asthma, rhinitis and chronic obstructive pulmonary disease (COPD) and a novel micronisation process for manufacturing a stable formulation for formoterol or its enantiomers and a carrier/diluent comprising a carbohydrate such as lactose.
    Type: Grant
    Filed: January 25, 2007
    Date of Patent: March 2, 2010
    Assignee: AstraZeneca AB
    Inventor: Eva Trofast
  • Patent number: 7662403
    Abstract: There is provided a powder formulation for nasal delivery including a protein having a molecular weight of 10 kDa or greater and chitosan or a derivative thereof or a salt of chitosan or a salt of a derivative of chitosan. Preferably the protein is human growth hormone.
    Type: Grant
    Filed: January 4, 2006
    Date of Patent: February 16, 2010
    Assignee: Archimedes Development Limited
    Inventors: Ann Margaret Dyer, Peter James Watts, Yu-Hui Cheng, Alan Smith
  • Patent number: 7591999
    Abstract: According to the present invention, a powdery preparation for nasal administration comprising a physiologically active substance, a non-water-absorbing and hardly water-soluble powder(s) and one or two selected from the group consisting of a mucolytic agent and a nonionic surfactant is provided.
    Type: Grant
    Filed: March 4, 2004
    Date of Patent: September 22, 2009
    Assignee: Mitsubishi Tanabe Pharma Corporation
    Inventors: Takahiro Matsuyama, Hiroyuki Yoshino
  • Patent number: 7582284
    Abstract: The present invention relates to active substances in particulate form, to methods for preparing them, to formulations containing them and to uses of such substances and formulations. A preferred embodiment is directed to particulate suspensions having improved flocculation behavior in a suspension vehicle, such as a hydrofluoroalkane propellant used in metered dose inhalers.
    Type: Grant
    Filed: April 14, 2003
    Date of Patent: September 1, 2009
    Assignee: Nektar Therapeutics
    Inventors: Andreas Kordikowski, Stephen Ernest Walker, Peter York
  • Patent number: 7572641
    Abstract: The present invention encompasses a method of evaluating pharmaceutical compositions of meloxicam whereby one can correlate in vitro properties to in vivo properties, and pharmaceutical compositions developed using the method.
    Type: Grant
    Filed: November 22, 2005
    Date of Patent: August 11, 2009
    Assignee: Teva Pharmaceutical Industries Ltd.
    Inventors: Michal Agami, Julia Hrakovsky, Ruth Tenengauzer
  • Patent number: 7566704
    Abstract: The invention pertains to compositions and therapeutic and prophylatic methods for treating/preventing infections in an animal or human by administering a soluble ?-glucan composition comprising ?-glucan molecules having an average molecular weight of at least 1,000,000 daltons, as determined by multi-angle laser light scattering (VHMW-glucan).
    Type: Grant
    Filed: January 17, 2006
    Date of Patent: July 28, 2009
    Assignee: Biopolymer Engineering, Inc.
    Inventors: Myra L. Patchen, Spiros Jamas, D. Davidson Easson, Jr., Gary R. Ostroff
  • Patent number: 7469488
    Abstract: Spray dried particles having specified aerodynamic characteristics are produced by atomizing a liquid feed and contacting the liquid feed with a drying gas, such as, for example, air or nitrogen. The humidity of the drying gas is controlled to a value, expressed, for instance, as dew point, which is known to produce particles having a specified tap density or aerodynamic diameter. Particles having a volume median geometric diameter greater than about 5 microns and a tap density less than about 0.4 g/cm3 are preferred.
    Type: Grant
    Filed: October 29, 2004
    Date of Patent: December 30, 2008
    Assignees: Alkermes, Inc., The Penn State Research Foundation
    Inventors: Donghao Chen, Richard P. Batycky, Lloyd Johnston, Jeffrey Mintzes
  • Patent number: 7470437
    Abstract: Methods of treating conditions with a metal-containing material are disclosed. The metal-containing material can be, for example, an antimicrobial material, an antibacterial material, an anti-inflammatory material, an anti-fungal material, an anti-viral material, an anti-cancer material, a pro-apoptosis material, and/or an MMP modulating material. In certain embodiments, the metal-containing material is an atomically disordered, silver-containing material.
    Type: Grant
    Filed: November 10, 2004
    Date of Patent: December 30, 2008
    Assignee: Nucryst Pharmaceuticals Corp.
    Inventors: Robert E. Burrell, John B. Wright, Kan Lam, Antony G. Naylor, Peter H. Moxham, Scott H. Gillis, Paul Schechter
  • Patent number: 7449236
    Abstract: Embolic particles, as well as their methods of use and manufacture, are described.
    Type: Grant
    Filed: August 8, 2003
    Date of Patent: November 11, 2008
    Assignee: Boston Scientific Scimed, Inc.
    Inventors: Janel L. Lanphere, Ernest J. Pierre, Greg Kapoglis, Thomas V. Casey, II
  • Patent number: 7427416
    Abstract: Methods of treating conditions using metal-containing materials are disclosed. Exemplary conditions include bacterial conditions, biofilm conditions, microbial conditions, inflammatory conditions, fungal conditions, viral conditions, autoimmune conditions, idiopathic conditions, hyperproliferative conditions, noncancerous growths, cancerous conditions and combinations of such conditions. In certain embodiments, the metal-containing material is an atomically disordered, nanocrystalline silver-containing material.
    Type: Grant
    Filed: October 22, 2003
    Date of Patent: September 23, 2008
    Assignee: Nucryst Pharmaceuticals Corp.
    Inventors: Scott H. Gillis, Paul Schechter, James Alexander Robert Stiles
  • Patent number: 7419971
    Abstract: Methods and compositions for enhancing the activity and/or duration of action of soft anti-inflammatory steroids of the haloalkyl 17?-alkoxy-11?-hydroxyandrost-4-en-3-one-17?-carboxylate type and the corresponding ?1,4 compounds and of anti-inflammatory steroids of the hydrocortisone and prednisolone type are described. The enhancing agents have the formula: wherein R is H or C1-C4 alkyl; Z1 is carbonyl or ?-hydroxymethylene; X1 is —O— or —S—; R5 is —OH, —OR6, —OCOOR6 or —OCOR7 wherein R6 is C1-C4 alkyl and R7 is C1-C4 alkyl, fluoromethyl or chloromethyl; and the dotted line in ring A indicates that the 1,2-linkage is saturated or unsaturated; with the proviso that when R is C1-C4 alkyl, then R5 is —OH.
    Type: Grant
    Filed: June 17, 2004
    Date of Patent: September 2, 2008
    Inventor: Nicholas S. Bodor
  • Patent number: 7387790
    Abstract: Nanoparticles made from a select group of lipids and optionally containing a therapeutically active agent are employed in pharmaceutical compositions for delivery to targeted tissues and/or cells for the treatment or diagnosis of such diseases as cancer.
    Type: Grant
    Filed: June 14, 2002
    Date of Patent: June 17, 2008
    Assignee: Cornerstone Pharmaceuticals
    Inventors: Robert Shorr, Robert Rodriguez
  • Patent number: 7291295
    Abstract: A method for precipitation of finely divided solid particles comprising a) Dissolving a compound C in a fluid A to provide a solution A; b) Thermostatization of said solution A to a temperature ranging between ?50°0 C. and 200° C.; c) Adding a fluid B to said solution A until a pressure P is obtained, characterized in that said fluid B at a pressure P is miscible with said solution A and acts as a co-solvent to form a solution AB; d) Adding an inert gas to solution AB so as to maintain the pressure P; and e) Reducing the pressure of said solution AB so as to produce the precipitation of said compound C, and wherein the method permits particles of average size less than 20 ?m, with a narrow distribution ranging between 1 and 100 ?m, from a solution, and not a mix, that contains the compound C precipitated.
    Type: Grant
    Filed: August 23, 2001
    Date of Patent: November 6, 2007
    Assignee: Sociedad Espanola de Carburos Metalicos, S.A.
    Inventors: Nora Ventosa Rull, Jaume Veciana Miro, Concepción Rovira Angulo, Santiago Sala Verges
  • Patent number: 7279457
    Abstract: Drug formulations for systemic drug delivery with improved stability and rapid onset of action are described herein. The formulations may be administered via buccal administration, sublingual administration, pulmonary delivery, nasal administration, subcutaneous administration, rectal administration, vaginal administration, or ocular administration. In the preferred embodiments, the formulations are administered sublingually or via subcutaneous injection. The formulations contain an active agent and one or more excipients, selected to increase the rate of dissolution. In the preferred embodiment, the drug is insulin, and the excipients include a metal chelator such as EDTA and an acid such as citric acid. Following administration, these formulations are rapidly absorbed by the oral mucosa when administered sublingually and are rapidly absorbed into the blood stream when administered by subcutaneous injection. In one embodiment, the composition is in the form of a dry powder.
    Type: Grant
    Filed: March 11, 2005
    Date of Patent: October 9, 2007
    Assignee: Biodel, Inc.
    Inventors: Roderike Pohl, Solomon S. Steiner
  • Patent number: 7276251
    Abstract: A sustained-release drug composition consisting essentially of microparticles of hyaluronic acid having a high molecular weight or an inorganic salt thereof and a protein or peptide drug encased in said microparticles, wherein the average size of said microparticles ranges from 0.1 to 40 ?m.
    Type: Grant
    Filed: July 26, 2002
    Date of Patent: October 2, 2007
    Assignee: LG Life Sciences, Ltd., Inc.
    Inventors: Myung-Jin Kim, Sun-Jin Kim, Oh-Ryong Kwon
  • Patent number: 7255881
    Abstract: Metal-containing materials, as well as their preparation and use are disclosed. The metal-containing material can be, for example, an antimicrobial material, an anti-biofilm material, an antibacterial material, an anti-inflammatory material, an anti-fungal material, an anti-viral material, an anti-cancer material, a pro-apoptosis material, anti-proliferative, MMP modulating material, an atomically disordered, crystalline material, and/or a nanocrystalline material. In certain embodiments, the metal-containing material is an atomically disordered, nanocrystalline silver-containing material.
    Type: Grant
    Filed: October 22, 2003
    Date of Patent: August 14, 2007
    Assignee: Nucryst Pharmaceuticals Corp.
    Inventors: Scott H. Gillis, Paul Schechter, James Alexander Robert Stiles
  • Patent number: RE40493
    Abstract: Paclitaxel is provided in a porous matrix form, which allows the drug to be formulated without Cremophor and administered as a bolus. The paclitaxel matrices preferably are made using a process that includes (i) dissolving paclitaxel in a volatile solvent to form a paclitaxel solution, (ii) combining at least one pore forming agent with the paclitaxel solution to form an emulsion, suspension, or second solution, and (iii) removing the volatile solvent and pore forming agent from the emulsion, suspension, or second solution to yield the porous matrix of paclitaxel. The pore forming agent can be either a volatile liquid that is immiscible with the paclitaxel solvent or a volatile solid compound, preferably a volatile salt. In a preferred embodiment, spray drying is used to remove the solvents and the pore forming agent.
    Type: Grant
    Filed: August 26, 2005
    Date of Patent: September 9, 2008
    Assignee: Acusphere, Inc.
    Inventors: Julie A. Straub, Howard Bernstein, Donald E. Chickering, III, Sarwat Khattak, Greg Randall